New hope for lung cancer: experimental drug combo enters trial

NCT ID NCT07609251

Not yet recruiting Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will receive the drugs by IV every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SCTB41 (an experimental drug) combined with docetaxel (a chemotherapy drug)
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced lung cancer who have already tried other therapies.
What could go wrong: This is an early phase II study with only 90 participants, so results are preliminary. The combination may cause significant side effects, and there is no guarantee it will be more effective than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.